« Return to News | CROs/Service Providers | Technology Solutions

Bio-Imaging Technologies Sells CapMed Division

Thursday, January 8, 2009 09:44 AM

Contract research organization (CRO) Bio-Imaging Technologies has sold off its CapMed division, which provides personal health management solutions to hospitals, employers and pharmaceutical companies, in order to better focus on the CRO’s core clinical trials business.

Under the terms of the agreement, Bio-Imaging will receive $500,000 in cash plus an earn-out over a two-year period from Metavante Technologies, a Milwaukee-based provider of banking and payment technologies.

“We believe that it is beneficial for all parties that CapMed will be a part of an organization that is more closely aligned with healthcare information and payment processing for consumers,” Bio-Imaging president and CEO Mark Weinstein said in a company release.

Bio-Imaging expects to incur a one-time charge of $2.5 to $2.7 million related to the write-down of assets of the CapMed division. As a result, the company has lowered its full year 2008 earnings per share guidance from a range of $0.23 to $0.25 per share to a range of $0.11 to $0.15 per share.

In early morning trading, Bio-Imaging’s share prices were up 2.56% to $3.20.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.